401
Participants
Start Date
November 26, 2018
Primary Completion Date
December 9, 2019
Study Completion Date
August 20, 2020
AbobotulinumtoxinA dose level 1 or 2
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
placebo
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
AbobotulinumtoxinA dose 3
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
AbobotulinumtoxinA dose 4
Intramuscular; 0.05 mL per injection site; single treatment of glabellar facial lines
Galderma Research Site, New York
Galderma Research Site, Chapel Hill
Galderma Research Site, Charlotte
Galderma Research Site, Coral Gables
Galderma Research Site, Mequon
Galderma Research Site, Chicago
Galderma Research Site, New Orleans
Galderma Research Site, Manhattan Beach
Galderma Research Site, Encino
Galderma Research Site, Vista
Lead Sponsor
Galderma R&D
INDUSTRY